Eisai signs licensing agreement with Henlius Biotech for lung cancer drug in Japan
Eisai will license Henlius Biotechs lung cancer drug Hansizhuang in Japan for up to 388 million dollars. The deal includes a 75 million dollar upfront payment.
Insights:
Eisai Co., Ltd. has entered into a licensing agreement with Shanghai Henlius Biotech, Inc. for the lung cancer drug Hansizhuang, according to an announcement on February 5, 2026. Under the terms of the agreement, Eisai Co., Ltd. will pay an upfront fee of $75 million to secure the rights to develop, manufacture, and commercialize the drug as an injection for oncology indications in Japan 
JP.
JP.
